0001127602-19-026527.txt : 20190813 0001127602-19-026527.hdr.sgml : 20190813 20190813160329 ACCESSION NUMBER: 0001127602-19-026527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190809 FILED AS OF DATE: 20190813 DATE AS OF CHANGE: 20190813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ACKERMANN CHRISTINA CENTRAL INDEX KEY: 0001681871 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 191020608 MAIL ADDRESS: STREET 1: 400 SOMERSET CORPORATE BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-08-09 0000885590 Bausch Health Companies Inc. BHC 0001681871 ACKERMANN CHRISTINA 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 1 EVP AND GENERAL COUNSEL Common Stock, No Par Value 2019-08-09 4 F 0 7779 22.39 D 53943 D Common Stock, No Par Value 2019-08-12 4 S 0 3418 22.4475 D 50525 D This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price in Column 4 reflects the average weighted sale price for the transactions aggregated on this Form 4. The sales price per share reported on this Form 4 range from $22.30 to $22.61. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares sold at each separate price. /s/ Kirsten O'Donnell, attorney-in-fact for Christina Ackermann 2019-08-13